Literature DB >> 22101651

BRACking news on triple-negative/basal-like breast cancers: how BRCA1 deficiency may result in the development of a selective tumor subtype.

Manuela Santarosa1, Roberta Maestro.   

Abstract

Mutations in the BRCA1 tumor suppressor predispose to the development of breast and ovarian cancers. Noticeably, the majority of BRCA1-associated breast cancers are triple-negative (ER-, PR- and HER2-) and display a basal-like phenotype, which are features relatively uncommon among sporadic breast cancers. It is well documented that BRCA1 is involved in a number of cellular functions converging to the maintenance of genomic stability. However, the control over DNA integrity does not seem to account for the peculiar phenotype of BRCA1-associated tumors since mutations in other genes involved in such a function, namely BRCA2, associate to a broader spectrum of breast carcinoma subtypes. Indeed, an increasing body of evidence indicates that BRCA1 is implicated also in the regulation of transcription by impinging upon general components of the transcriptional machinery. Thus, elucidating the complex biochemical network regulated by BRCA1 may allow a better understanding also of the biology of sporadic triple-negative/basal-like tumors and lay down the basis for novel preventive measures and more effective therapeutic strategies. This review summarizes recent findings on the role of BRCA1 in the regulation of transcription and how this might set the ground for the development of cancers with triple-negative/basal-like features.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22101651     DOI: 10.1007/s10555-011-9336-6

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  5 in total

1.  BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.

Authors:  Amanjit Bal; Sangeeta Verma; Kusum Joshi; Anuj Singla; Ravi Thakur; Sunil Arora; Gurpreet Singh
Journal:  Virchows Arch       Date:  2012-07-21       Impact factor: 4.064

2.  53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway.

Authors:  Jing Yao; Ai Huang; Xiumei Zheng; Tao Liu; Zhenyu Lin; Sheng Zhang; Qin Yang; Tao Zhang; Hong Ma
Journal:  J Cancer Res Clin Oncol       Date:  2016-11-12       Impact factor: 4.553

3.  Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle.

Authors:  Stoil D Dimitrov; David Lu; Nana Naetar; Yiduo Hu; Shailja Pathania; Chryssa Kanellopoulou; David M Livingston
Journal:  Genes Dev       Date:  2013-10-15       Impact factor: 11.361

4.  Mesenchymal traits are selected along with stem features in breast cancer cells grown as mammospheres.

Authors:  Silvia Borgna; Michela Armellin; Alessandra di Gennaro; Roberta Maestro; Manuela Santarosa
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

5.  First description of an acinic cell carcinoma of the breast in a BRCA1 mutation carrier: a case report.

Authors:  Carla B Ripamonti; Mara Colombo; Patrizia Mondini; Manoukian Siranoush; Bernard Peissel; Loris Bernard; Paolo Radice; Maria Luisa Carcangiu
Journal:  BMC Cancer       Date:  2013-02-01       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.